The Institute for Gene Therapies (IGT) has launched, with the aim of maximizing the potential of gene therapies…
Mary Chapman
Mary graduated from Wayne State University with a degree in journalism. She began her career at United Press International, then spent a decade reporting for the Bureau of National Affairs, Inc. (now Bloomberg Industry Group). Mary has written extensively for The New York Times, and her work has appeared in publications such as Time, Newsweek, Fortune, and the Chicago Tribune. She’s won a Society of Professional Journalists award for outstanding reporting.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Mary Chapman
An abundance of events are afoot around the world to mark Rare Disease Day 2020 on Feb. 29. The…
Kevin Schaefer hadn’t been in an airport since he was 4 years old, so he had been looking forward to…
The Muscular Dystrophy Association (MDA) has awarded AavantiBio $1,076,232 to advance the biotechnology company’s development of a…
Online forums have markedly altered how patients, caregivers and healthcare professionals communicate and connect. Even when miles apart,…
A new data-sharing platform recently launched by the Critical Path Institute’s (C-Path) Data Collaboration Center (DCC) and the…
Scores of events are afoot worldwide to mark Feb. 28, Rare Disease Day 2019. The activities aim to raise awareness about…
Neurocrine Biosciences and Voyager Therapeutics have formed an alliance in hopes of bringing potentially life-changing treatments to market…
The U.S. Food and Drug Administration(FDA) is updating its 2015 draft guidelines for drug discovery in rare diseases, with…